The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 17, 2017.
Transcript:
Hi, I’m Kelly Davio for the Center for Biosimilars, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars. Here are our top 5 biosimilars articles for the week of July 17:
Number 5: A new report shows that most US-based health plans now cover at least 1 of the 2 available FDA-approved biosimilars.
Number 4: A phase 3 trial of the proposed rituximab biosimilar candidate GP2013 shows positive results in patients with follicular lymphoma.
Number 3: Molly Billstein Leber, manager of Medication Policy and Formulary Management for the Yale New Haven Health System, discusses the FDA’s Oncologic Drugs Advisory Committee’s unanimous recommendation of approval for biosimilars to Avastin and Herceptin.
Number 2: At this week’s public meeting on the Hatch-Waxman Amendments, FDA Commissioner Dr Scott Gottlieb announced the upcoming publication of 2 documents related to the ANDA process.
And finally, Number 1: The FDA Reauthorization Act may proceed to a Senate vote sooner rather than later after the failure of the Better Care Reconciliation Act.
Read these articles and more at centerforbiosimilars.com
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.